Peter Chambré


Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies. He was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of…

read more

Friedrich von Bohlen und Halbach, Ph.D

Friedrich von Bohlen und Halbach, Ph.D Dr Friedrich von Bohlen und Halbach is managing partner at Dievini Hopp Biotech Holding GmbH & Co.KG, the company managing the life science activities and investments of Dietmar Hopp. In addition, he is board...

read more

Christof Hettich, L.L.D

Christof Hettich, L.L.D Prof Dr Hettich has extensive experience in the legal, financial and economical aspects of structuring and restructuring of medium-sized and public companies; equity investments of start up companies; mergers and acquisitions and...

read more

Matthias Kromayer, Ph.D

Matthias Kromayer, Ph.D Matthias Kromayer is a member of the Executive Board of MIG Verwaltungs AG, responsible for the MIG Funds’ holdings in the life sciences. He is a Member of the Advisory Boards of Virologik GmbH and Cerbomed GmbH. Prior to MIG, he...

read more

Prof Erich Schlick, M.D

Prof Erich Schlick, M.D Wellington Partners Prof Dr Erich Schlick has over 25 years of experience in the healthcare sector. Erich Schlick spent five years at the US National Cancer Institute, and over 15 years with BASF Pharma, including ten years as the...

read more

Harald F. Stock, Ph.D

Harald F. Stock, Ph.D Harald Stock serves on the Board of Directors of Immatics and is a member of its Audit and Human Resources Committees. Harald has been President & Chief Executive Officer of Malmö, Sweden based ArjoHuntleigh AB, a leading medical...

read more